AbbVie Earnings: Revenue and Margins Rebound, but Valuation Looks Full

AbbVie's Q2 FY2026 revenue was $16.99B, up from $15.42B in Q2 FY2025. That represents year-over-year growth of 10.2%, a $1.57B increase. No company guidance or consensus estimate was included in the supplied materials, so the appropriate report-card reference is the same quarter one year earlier.

Profitability improved faster than revenue. Operating income reached $6.43B, equivalent to a 37.9% operating margin. The corresponding Q2 FY2025 operating margin was 31.7%, meaning the latest quarter expanded by 6.2 percentage points. This is the clearest positive change in the print because it indicates that a larger portion of each revenue dollar reached operating profit.

Gross profit was $12.07B, producing a gross margin of 71.0%. The supplied Q2 FY2025 table does not contain a usable gross-margin figure, so a year-over-year comparison cannot be made. The reported gross margin nevertheless provides an important baseline for determining whether the improvement in operating profitability persists in subsequent periods.

EPS increased to $2.03 from $0.52 in Q2 FY2025. The $1.51 per-share increase is substantially larger than the rate of revenue growth, consistent with the stronger operating margin. Net income was $3.61B, or 21.3% of revenue, although the supplied quarterly table does not provide a comparable year-ago net-income figure.

Cash generation was also meaningful. The latest XBRL point values show $3.83B of cash flow from operations and $265M of capital expenditure. Subtracting the two produces $3.56B of free cash flow. A year-ago quarterly cash-flow reference was not disclosed, so this metric cannot be classified as a beat despite the positive absolute result.

Sequentially, revenue increased from $15.00B in Q1 FY2026 to $16.99B in Q2, while operating margin rose from 26.6% to 37.9%. EPS increased from $0.39 to $2.03. Sequential comparisons can be affected by seasonality and timing, which are not detailed in the supplied information, but the scale of the improvement confirms that Q2 was materially stronger than the preceding quarter.

The quarter supports a straightforward operating thesis: AbbVie produced higher sales while converting more of those sales into operating profit. Revenue growth alone would be less informative if margins were declining. Instead, the combination of 10.2% revenue growth and 6.2 percentage points of operating-margin expansion produced a much larger improvement in EPS.

The remaining question is durability. The quarterly history is volatile: operating margin was 31.7% in Q2 FY2025, 12.1% in Q3 FY2025, 26.6% in Q1 FY2026 and 37.9% in the latest quarter. Some quarterly values may reflect items that are not separately disclosed in the supplied data. Without an earnings release explaining those movements, it would be premature to treat 37.9% as a new steady-state margin.

Cash flow provides a second point of support, but it requires similar caution. The $3.56B quarterly free-cash-flow result is healthy in isolation. The more stable reference is full-year 2025 free cash flow of $17.82B, almost unchanged from $17.83B in 2024 but below $22.06B in 2023 and $24.25B in 2022. The valuation therefore uses 2025 free cash flow rather than annualizing one strong quarter.

Balance-sheet risk remains material. AbbVie had $64.50B of debt against $6.57B of cash, resulting in $57.93B of net debt. Shareholders' equity was negative $5.94B. Negative book equity does not determine intrinsic value, but in combination with the debt balance it reduces flexibility if operating performance or cash generation weakens.

Overall, Q2 improves confidence in current operating momentum but does not establish that the company has entered a permanently higher-margin period. That distinction matters because the market price already requires sustained cash generation. The print is positive for business performance and neutral for the stock thesis at $253.70.

There is no prior SageNoodle valuation to update, so this article initiates rather than raises fair value. We value AbbVie using a multiple of normalized free cash flow. The normalized starting point is the $17.82B reported for calendar 2025, divided by 1.771B shares. That equals approximately $10.06 of free cash flow per share.

The base case applies a 25 times multiple to $10.06 of free cash flow per share, producing fair value of $251.6. This assumption requires broadly stable annual cash generation and continuation of the latest revenue and margin direction without treating Q2's 37.9% operating margin as permanent. At the current price of $253.70, the shares trade 0.8% above base fair value and qualify as Fairly Valued under the stated 15% valuation bands.

The bear case applies a 14 times multiple to the same 2025 free-cash-flow base, resulting in $140.9 per share. This outcome would be consistent with declining cash flow, margin normalization and a higher required return because of the debt burden. The bull case applies a 32 times multiple, producing $322.0 per share. That case requires the latest operating improvement to persist and free cash flow to remain at least near the 2025 level.

At the current market capitalization implied by 1.771B shares, 2025 free cash flow represents a 4.0% yield. The reported 2025 EPS of $2.36 also implies a trailing P/E of approximately 107.5 times, although EPS has been volatile and may be affected by items not separated in the supplied data. EBITDA was not disclosed, so no meaningful EV/EBITDA multiple can be calculated.

The conclusion is that Q2 was better, but the valuation already reflects substantial confidence in durable cash generation. The quarter justifies initiating fair value near the current share price rather than assigning an immediate premium for one period of unusually strong margin performance.

The most direct challenge to the base case would be sustained operating margins near or above the Q2 level. If subsequent quarters confirm that the 37.9% margin is durable rather than temporary, the 2025 free-cash-flow base may prove too conservative and the bull case would become more relevant.

The opposite risk is that Q2's margin improvement reverses. The recent quarterly record contains substantial operating-margin and EPS volatility. A return toward the weaker periods would undermine the 25 times free-cash-flow multiple, particularly because the current price provides little discount to base fair value.

Cash conversion could also disappoint. The valuation assumes that $17.82B of 2025 free cash flow is a reasonable normalized base. If cash flow from operations declines or capital requirements increase, fair value would fall even if reported revenue remains stable. Conversely, cash flow consistently above that baseline would make the present framework conservative.

Finally, leverage could magnify an operating setback. Net debt of $57.93B and negative shareholders' equity create less room for error than the income statement alone suggests. The thesis would weaken if debt remained elevated while annual free cash flow moved materially below the 2025 level. It would strengthen if AbbVie converted the current profit improvement into sustained cash generation and a lower debt balance.